Given the recognized impact of FGFR4-R388 [21]–[25] and of the GH/IGF-I axis on cancer progression [44], the current findings identify the common FGFR4 polymorphism as an endocrine signal participating in these processes. The gene discussed is FGFR4; the disease is cancer.